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Abstract
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Fast, selective, and noninvasive reporting of intracellular cancer-associated events and species will
lead to a better understanding of tumorigenesis at the molecular level and development of
precision medicine approaches in oncology. Overexpressed reductase presence in solid tumor cells
is key to cancer progression and protection of those diseased cells from the oxidative effects of
therapeutics meant to kill them. Human NAD(P)H:quinone oxidoreductase isozyme I (hNQO1), a
cytoprotective 2-electron-specific reductase found at unusually high activity levels in cancer cells
of multiple origins, has attracted significant attention due to its major role in metastatic pathways
and its link to low survival rates in patients, as well as its ability to effectively activate quinonebased, anticancer drugs. Accurate assessment of hNQO1 activities in living tumor models and
ready differentiation of metastases from healthy tissue by fluorescent light-based protocols
requires creation of hNQO1-responsive, near-infrared probes that offer deep tissue penetration and
low background fluorescence. Herein, we disclose a quinone-trigger-based, near-infrared probe
whose fluorescence is effectively turned on several hundred-fold through highly selective
reduction of the quinone trigger group by hNQO1, with unprecedented, catalytically efficient
formation of a fluorescent reporter. hNQO1 activity-specific production of a fluorescence signal in
two-dimensional cultures of respiring human cancer cells that harbor the reductase enzyme allows
for their quick (30 min) high-integrity recognition. The characteristics of the near-infrared probe
make possible the imaging of clinically relevant three-dimensional colorectal tumor models
possessing spatially heterogeneous hNQO1 activities and provide for fluorescence-assisted
identification of submillimeter dimension metastases in a preclinical mouse model of human
ovarian serous adenocarcinoma.
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Although initially thought to be protective of only healthy tissue cells by their ability to
combat cancer-initiating reactive oxygen species (ROS),1 certain reductases that are
upregulated in various tumor-derived cell lines and especially those tumor cells experiencing
hypoxic conditions are pivotal to their survival during prolonged oxidative attack,2 the latter
being the major cell-killing pathway provided by chemo- and radiotherapies.3 Importantly,
metastasis from primary solid tumors to other sites can occur via a redox-based escape
mechanism that relies upon adaptive cancer cells possessing significantly elevated levels of
ROS-combating reductases,2 and the ability to change phenotype in order to exist as
isolated, individual cells.4 As a result, the presence of said reductases at upregulated values
within cancer cells, such as human NAD(P)H:quinone oxidoreductase isozyme I (hNQO1)
that has been found at elevated levels in more than 50% of the NCI-60 tumor cell line
database,5,6 has been identified as key in the development of a new generation of anticancer
drugs (e.g., mitomycin C,7β-lapachone,8,9 deoxynyboquinones10) whose success is derived
from their selective reductase activation.
Interestingly, only recently have the tools been investigated that are necessary to leverage
upregulated, cytoprotective reductase presence in human cancer cells, so as to allow the
latter’s identification, imaging, and study.11–14 This nascent field poses a great challenge for
the measurement and imaging science communities with regard to creation of approaches
that selectively and sensitively report on overexpressed reductase activity in living cancer
tissues. Such yet-to-be-implemented approaches will have a potentially large impact on
knowledge regarding tumorigenesis and metastasis, as well as in precision medicine-based
diagnoses and treatments of cancer. Turn-on, enzyme substrate probe-based
fluorescence15–18

Author Manuscript

Turn-on, enzyme substrate probe-based fluorescence15–18 holds much promise as a
transduction path for the determination of cytoprotective reductase presence and activity
within tissue cells, with the caveat that its successful application requires the existence of
fluorescently silent, reductase-sensitive probes that can efficiently penetrate into cells and
then be selectively and rapidly converted to a highly fluorescent reporter by the enzyme. The
resulting emitted light from an appropriately designed reporter has the potential to describe
the temporal and spatial dependence of reductase activity within a single cell or in two- and
three-dimensional assemblies of cells. In addition, it may be possible that upregulated
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enzyme activities in abnormal cells will yield a fluorescence signal that is sufficient to allow
for differentiation of diseased and healthy tissue with cellular resolution. To date, a select
group of endogenous reductases has been targeted in the development of turn-on fluorescent
probes that can be used to image and detect human cancer cells overexpressing a given
reductase, including nitroreductases,19–23 human aldo-ketoreductase,13 thioredoxin
reductase,11 and hNQO1.14,24–26 However, for end-goal applications that target the study of
microenvironmental effects27 in three-dimensional multicellular tumor mimics28 and their
use in drug evaluation studies,29,30 and realtime determination of borders between cancerous
and normal tissues during surgery,31–34 not only must the optical properties of a probe be
distinctly different from those of the reductase-generated fluorescent reporter so as to yield a
high target-to-background signal ratio14,35 but the energies for reporter excitation and
emission should lead to less tissue absorption and scattering events—a scenario achieved at
wavelengths above 600 nm.32,33 At the time of this writing, there are no reports of
reductase-sensitive probes that meet these criteria.

Author Manuscript

hNQO1, aka DT-diaphorase, is a cytosolic, two-electron-specific reductase whose
expression is regulated by the Kelch-like, ECH-associated protein 1 (Keap1)/nuclear factor
E2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway, similar to other
cytoprotective reductases.2,3,5 Under normal cellular conditions, the Keap1 protein binds to
the Nrf2 transcription factor to promote its demise through ubiquitination followed by
proteasomal degradation. However, in response to increased oxidative stress, Keap1 loses its
capability to target and degrade the Nrf2 transcription factor, due to oxidation of cysteine
sites in Keap1. As a result, Nrf2 is transported into the nucleus where it accumulates and
binds to an ARE sequence, thereby triggering hNQO1 expression.36–38 In normal cells,
hNQO1 levels are typically low, but the enzyme is known to be highly upregulated in many
types of cancer cells and solid tumors,6,39 and in particular, those cancers that are or have
become resistant to chemo- and radiotherapies.40–42 Importantly, hNQO1 overexpression
has been directly linked to tumorigenesis and cancer stem cell phenotype,4,43 as well as poor
patient survival.44–48 Therefore, development of hNQO1-activatable profluorogenic probes
that target the elevated hNQO1 found in solid tumors is useful for understanding enzymatic
processes at the molecular level and developing tools to determine borders between diseased
and healthy tissue during fluorescence-assisted surgery.

Author Manuscript

We report here the development and in vitro and in vivo evaluation of a profluorogenic
probe, Q3STCy, whose latent electron-transfer-quenched NIR fluorescence is selectively
turned on by hNQO1 reduction of the Q3 trigger group to yield the corresponding
fluorescent reporter TCy, Scheme 1. A unique feature of the quinone reductase-triggered,
near-infrared (NIR) probe/reporter system is the low background signal that results from the
significant difference in probe and reporter excitation and emission energies, an outcome
achieved by use of a self-eliminating, electronically altering linker. Importantly, the latter
yields an unprecedented probe activation efficiency, paving the way for probe use in realtime imaging applications. To that end, the energies for TCy reporter excitation and emission
are such that tissue damage and autofluorescence background signal limitations are not
concerns, thereby demonstrating the advantages of the new probe-reporter system versus
extant NQO1-responsive probes.14,24–26,49 Furthermore, the carefully crafted NIR probe/
reporter system does not suffer from structural alterations or changes in reporter signal
ACS Chem Biol. Author manuscript; available in PMC 2021 February 23.
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transduction that result from the presence of biologically active, potentially cross-reactive
species in the cellular milieu; such events have impeded progress in the development of
activatable NIR probes. Finally, we show that the new NIR probe is capable of detecting
hNQO1 activity in two- and three-dimensional cultures of human cells and an in vivo
preclinical tumor model, allowing for identification of tiny ovarian cancer tumors.

RESULTS AND DISCUSSION
Design, Preparation, and Characterization of the Q3STCy Probe.

Author Manuscript
Author Manuscript

To achieve a successful profluorogenic hNQO1-specific probe of practical application in
several disciplines, many design factors need to be carefully considered. hNQO1 is an
intracellular enzyme present mainly within the cytosol; its location can provide an advantage
for numerous applications, especially those for which retention of hNQO1 generated
reporter within target cells offers their ready discrimination from nontarget normal cells or
the ability to provide quantitative information on cellular enzyme activity levels. For
example, such a scenario is a prerequisite for successful real-time cytoreductive surgical
removal of cancerous tissue that requires sustained, time-invariant, target-to-background
ratios (TBRs).35 Furthermore, this tack will allow for correlation of prodrug efficacy and
their hNQO1-based activation in cellular assays.50 To that end, cell membrane permeability
of the probe and cellular retention of the resulting reporter are essential for the development
of hNQO1-activatable probes. In addition, for an effective reporting of cellular hNQO1
activities, the probe will be recognized and activated selectively by hNQO1 without any
interference from competing reducing agents (e.g., biothiols and reductases) found in the
complex physiological environment. Furthermore, to achieve remarkable TBR values as a
result of ready differentiation of the reporter emission signal from the background, the probe
and the reporter will have distinct photophysical properties. As such, the reporter will have
photostable emission that occurs at an energy much different than that of absorption (λabs vs
λem, large Stokes shift), is insensitive to pH changes, and yields a high brightness (ε × Φ).
In contrast, the unactivated probe is to possess a low fluorescence quantum efficiency,
significantly different absorption and emission profiles from the reporter, and good
environmental stability.

Author Manuscript

With these criteria in mind, the tricarbocyanine TCy (Scheme 1) was selected as the reporter
because of its anticipated NIR absorption/emission wavelengths that possess large Stokes
shifts, high quantum efficiency, and photo-stability.51,52 Importantly, the methylamine group
in its meso position provides a synthetic handle that can be functionalized with an hNQO1
specific trigger (Q3). Small changes in the electronic properties of substituents at the meso
position can induce large changes in photophysical properties of the TCy reporter due to the
nature of its π-electron density distribution.53,54 Introduction of an electron-withdrawing
carbamate bond at the meso position is posited to significantly alter the electron density on
the backbone of the TCy, thereby generating dramatic changes in the photophysical
properties of the TCy reporter. The trimethyl locked quinone propionic acid Q3 motif has
been successfully demonstrated as a highly selective hNQO1 substrate, capable of being
catalytically reduced to its hydroquinone with NADH cofactor; this trigger group has been
targeted in the design of bioreductive prodrugs,55–58 nanomaterials,59,60 drug delivery
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systems,61 and imaging probes.14,24–26,49 Furthermore, in the Q3STCy probe, the Q3 group
will not only act as an hNQO1-specific trigger, but its electron-deficient nature is anticipated
to allow it to be an effective photoinduced electron-transfer (PeT) quencher of the
fluorescence of the covalently linked TCy reporter. Finally, the self-eliminating 2mercaptoethanol linker between the Q3 trigger and the bulky TCy reporter is expected to
result in enhanced enzyme activation of Q3STCy.62
The synthetic route for Q3STCy is outlined in Scheme S1. To help provide a rationale
regarding the unreported spectroscopic properties of Q3STCy, as well as investigate the
influence of Q3PA on the photophysical properties of Q3STCy, a structural analogue of
Q3STCy, namely iBuTCy without the Q3PA moiety, was also prepared. All compounds were
characterized with 1H NMR, 13C NMR, and ESI-HRMS and gave satisfactory outcomes
(Supporting Information).

Author Manuscript

Photophysical Properties.
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As shown in Figure 1, the spectral behavior of the Q3STCy probe and TCy reporter was
measured in phosphate-buffered aqueous solution (PBS, pH = 7.4). In contrast to the
Q3STCy probe, the TCy reporter has distinct spectroscopic properties that are anticipated to
allow for ready differentiation of a reporter signal from that of the probe in complex
biological environments. Of particular note is the large difference in maximum energy of
absorption for the TCy reporter (λabsreporter = 606 nm) and the Q3STCy probe (λabsprobe =
786 nm), as well as the significant difference in peak emission wavelength (λemreporter = 755
nm vs λemprobe = 798 nm). The dissimilarities in energies of absorption and emission for the
TCy reporter and Q3STCy probe, caused by introduction of a carbamate bond at the meso
position, were examined by investigating the HOMO and LUMO energy levels53 of TCy and
an analogue of the Q3STCy probe that also possesses a carbamate moiety, dubbed iBuTCy
(Scheme S1). The latter is structurally similar to the Q3STCy probe, but iBuTCy is more
facile to study with computational methods. As determined from semiempirical DFT
calculations (B3LYP/6–31G, Figure S4), the energy difference of 1.35 eV in the HOMO and
LUMO of iBuTCy is 0.28 eV smaller than the 1.63 eV value for TCy, thereby providing
rationale for the observed longer absorption/emission wavelengths of iBuTCy, and thus the
Q3STCy probe, vs those of the reporter. The ability to use, in cellular imaging experiments,
an excitation energy that leads to large reporter absorption but almost nonexistent probe
absorption is expected to result in a much attenuated background signal from probe
fluorescence, in turn leading to high contrast between target cells and nontarget cells.
Additionally, the exceedingly large Stokes shift of the TCy reporter (149 nm) is attributed to
formation of an ICT state.51 Such a difference in reporter absorption/emission energies will
minimize possible reporter self-quenching and thereby provide a high target signal, as well
as lead to decreased background associated with scattering of the excitation light.
As expected from the design parameters discussed above, the Q3STCy probe is much less
fluorescent in aqueous solution than is its corresponding TCy reporter. Quantum yield values
(Φ) of Q3STCy and TCy were determined from their aqueous solutions (2% DMSO: 98%
PBS, pH = 7.4) using indocyanine green in water (Φ = 0.012)63 and in-house-synthesized
1,1′,3,3,3′,3′-hexamethyl-3,5-propylene-4-(dimethylamino)-2,2′-indotricarbocyanine
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perchlorate (HPDITCP) in ethanol (Φ = 0.161) as standards.64 Q3STCy possesses a quantum
yield (0.0046) that is 14-fold lower than that of the TCy reporter (Φ = 0.063), Table S1.
Through use of the Rehm-Weller equation, in conjunction with voltammetric half-wave
potentials and spectroscopic data (Figure S3), a free energy change of -0.47 eV is computed
for the donor-excited photoinduced electron-transfer (d-PeT) quenching of the Q3STCy
probe, indicating that electron transfer from the excited state of the TCy fluorophore to the
electron-deficient quinone moiety is a thermodynamically feasible process. Thus, Q3 is an
effective quenching group capable of substantially decreasing the fluorescence quantum
efficiency of Q3STCy. Furthermore, when irradiated near the maximum absorption of the
TCy reporter at 600 nm—186 nm less energetic than the absorption peak of the Q3STCy
probe—the reporter offered a 240-fold higher emission intensity at 765 nm compared to
Q3STCy, which is rationalized by the ~10× higher molar absorptivity of the TCy reporter. In
sum, the Q3STCy probe/TCy reporter system possesses the required spectral characteristics
to make it a strong candidate as a turn-on sensor of hNQO1 activity.
Fluorescence Turn On by hNQO1
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We next examined the efficacy of Q3STCy activation by hNQO1 under physiological
conditions (37 °C in 0.1 M, pH 7.4 PBS). The absorption and emission spectra of Q3STCy
solutions were recorded over time upon introduction of 688 U mL−1 of hNQO1 with added
100 μM NADH cofactor. A total of 1 U of hNQO1 will reduce 1 nmol of cytocytochrome c
min−1 in the presence of menadione substrate at 37 °C;24 the value of 688 U mL−1 is
approximately that found for hNQO1 in HT-29 colorectal cancer cells (761 ± 18 U mL−1,
assuming an average cell volume of 1 pL)65 using dichlorophenolindophenol as the redox
mediator,66 vide infra. As shown in Figure 2A, hNQO1 presence leads to a rapid decrease in
the intensity of the absorption band maximum of Q3STCy at 785 nm (50% decrease in 3
min, 90% decrease in 10 min), while the intensity of a new band centered at 606 nm,
presumed to be that of the TCy reporter, increases concomitantly (50% increase in 6 min,
90% increase in 15 min); there was an obvious change in solution color from green to blue.
Furthermore, the fluorescence emission exhibited an immediate increase at 798 nm,
followed by a larger change in intensity at the peak value of the TCy reporter (755 nm) that
led to a 193-fold increase in fluorescence within 20 min, Figure 2B. These spectral changes
are assigned to initial formation of a fluorescent intermediate of Q3STCy possessing an
intact carbamate bond, referred to as STCy, which has spectral properties similar to those of
iBuTCy; Scheme 1. Thus, we associate hNQO1 generation of STCy with the initial
fluorescence increase at 798 nm. Subsequent intensity increases at the emission maximum of
the TCy (755 nm) are attributed to its formation upon intramolecular cyclizative cleavage of
the five-membered 1,3-oxathiolan-2-one (aka thiolanone) in Scheme 1. Mass spectrometry
data support these conclusions, vide infra.
To investigate that the hNQO1-induced fluorescence turn on was indeed caused by the
release of TCy via the proposed mechanism in Scheme 1, solutions of Q3STCy treated with
688 U mL−1 of hNQO1 for 20 min under physiological conditions (37 °C in pH 7.4 PBS)
were analyzed by HPLC coupled to ESI-TOF mass spectrometry (Figure S5). Four of the
expected products were successfully separated and identified, having m/z values of 235.1356
[HQ3-L + H]+, error = 11.5 ppm; 610.3458 [STCy]+, error = 1.4 ppm; 506.3539 [TCy]+,
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error = 0.8 ppm; and 842.4639 [Q3STCy]+, error = 8.6 ppm. No H2Q3STCy was detected, as
expected, due to its rapid cyclization to HQ3-L (kcycle ~ 1 min). We assume that the
thiolanone coelutes with solvent between 1 and 2 min. These results confirm the initial
formation of STCy upon Q3STCy treatment by hNQO1, with subsequent TCy release.
However, due to differences in ionization efficiencies, we are unable to state how much of
the individual species exist with respect to each other after the 20 min incubation period.
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To obtain quantitative information on hNQO1 efficacy in activating Q3STCy, the apparent
kinetic parameters were determined by monitoring the release of the TCy reporter, as noted
by fluorescence emission at λem = 755 nm (λex = 605 nm), using various Q3STCy probe/
substrate concentrations (0.5–5 μM), Figure 3A. The TCy fluorescence intensity was
converted to concentration by using a linear calibration curve. Upon fitting the TCy
production rate to the Michaelis-Menten equation, an apparent Michaelis constant Km = 1.1
± 0.5 μM (standard deviation; n = 3) and maximum velocity Vmax = 0.31 ± 0.05 μmol min−1
mg hNQO1−1 were obtained. On the basis of these values, the catalytic constant or turnover
number kcat = 0.162 ± 0.024 s−1 and the catalytic efficiency kcat/Km = 1.5 ± 0.7 × 105 M−1 s
−1 were calculated. As of this writing, the bimolecular rate constant (kcat/Km) is the highest
reported for any probe of hNQO1 activity obtained under physiological conditions (pH 7.4,
0.1 M PBS). For example, the kcat/Km value for other hNQO1 probes ranges from 5 to 35 ×
103 M−1 s−1, which is 5–30 times slower than that afforded by the Q3STCy probe. We
attribute these favorable probe properties to the presence of the self-eliminating 2mercaptoethanol linker that separates the Q3 enzyme trigger group from the bulky TCy
reporter. This scenario allows for ready access of the trigger group to the active site of the
enzyme—as we have shown in computational and enzyme kinetics studies,62 thereby
yielding rapid activation of Q3STCy by hNQO1—and it also leads to a hydrolytically stable
probe whose fluorescence is effectively quenched in aqueous media. These characteristics
are demonstrated with results from time-drive experiments, Figure 3B, wherein was
monitored over time the fluorescence of two Q3STCy solutions with or without added
hNQO1. In the presence of hNQO1, the fluorescence signal due to TCy formation rapidly
increased (50% of maximum in 11 min) and reached a plateau near 30 min. There was no
significant change in fluorescence signal in the absence of hNQO1, even after 150 min, the
longest time examined.
Q3STCy and TCy Stability and Enzyme Selectivity.
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In order to successfully examine enzyme activity levels during in vitro and in vivo studies, it
is paramount that the probe provide a highly selective response to the enzyme of interest and
both probe and reporter be stable in the absence of the target enzyme. Biological species,
oftentimes present in tissue and cells at concentration levels several hundreds to thousands
of times higher than probes and reporters used to interrogate a target, have the potential to
yield either a false positive report of target presence that is caused by nonselective activation
of the trigger group or a low sensitivity response for a given target that results from
deactivation of the target-generated fluorescent reporter. The requisite characteristics for a
successfully implementable probe/reporter system can be more challenging to obtain for
probes whose reporters provide a fluorescence signal in the far-green and near-infrared
energy regions, as the structures of the probe and reporter must be carefully crafted to
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provide LUMO and HOMO energy levels that do not lead to interferent-induced redox
reactions or quenching events, such as those caused by NADH or glutathione present at
levels typical of the cellular environment.24
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To rule out possible activation of Q3STCy by hydrolysis or any interfering biological
reductants (e.g., thiols67 and other quinone reductases) potentially present and known to be
present in mammalian cells, the fluorescence response of Q3STCy solutions exposed to
various pH conditions and select species was evaluated. As expected, there was no apparent
impact of solution pH over the range of 4.5 to 9.5, Figure S6. Importantly, there was no
significant change in fluorescence even after 20 min of incubation of the probe with 1 mM
glutathione (GSH), ascorbic acid (AA), L-cysteine (Cys), L-homocysteine (Hcy), or
dithiothreitol (DTT), all in the absence of hNQO1 cofactor NADH; the results are shown in
Figure 4. On the basis of known reactions of NRH:quinone oxidoreductase 2 (QR2, aka
NQO2) and cytochrome P450 reductase (CPR) with certain quinone species,14,24 we
investigated their potential to activate the Q3STCy probe in the presence of their respective
cofactors, NRH and NADPH; the individual influence of the latter two cofactors on the
probe were also studied. A response roughly 20% of that for hNQO1-catalyzed NADH
activation of the Q3STCy probe was found when using an NQO2 activity 275 times the
highest reported NQO2 activity level in human cancer cells, the latter being a mere 0.2% of
the hNQO1 activity present in the same tumor-derived cancer cell line.68 It is important to
note the NQO2 cofactor NRH is not native to cells at concentration levels high enough to
allow for NQO2 activation of quinone substrates, and NRH is unstable in cellular and
aqueous environments.68 CPR, in the presence of NADPH cofactor, produced a fluorescence
response approximately 10% that of the signal for hNQO1-catalyzed activation of the probe,
even though the CPR activity used here is roughly that found in lung cancer cell
monolayers69 and 4% of the hNQO1 activity in colorectal cancer xenografts.70 Furthermore,
neither hNQO1 nor NADH was independently capable of inducing release of the reporter.
These outcomes are significant in the use of the Q3STCy probe to identify hNQO1 activity
in cancer cells, as they demonstrate the high selectivity of probe activation by hNQO1.

Author Manuscript

To examine the stability of the selectively released TCy reporter, we studied the effects of
pH and biological reductants (GSH, AA, Cys, Hcy, DTT) on the fluorescence signal of TCy
solutions. As shown in Figure S6, variation of aqueous pH (4.5–9.5) did not result in any
meaningful changes in the fluorescence intensity of the TCy reporter. Moreover, the
reporting capability of TCy was not influenced by the presence of these biological reducing
species, as demonstrated by the lack of any significant variations (<10%) in reporter
response in comparison to its incubation in PBS for 2 h, Figure S7. In total, the
characteristics of the Q3STCy probe and TCy reporter bode well for biological imaging
applications.
Fluorescence Imaging of Endogenous hNQO1 in Tumor-derived Cancer Cell Monolayers.
Reassured by the effective and selective nature of Q3STCy in detecting hNQO1 activity in
vitro, we used confocal microscopy to investigate the ability of Q3STCy to identify and
differentiate tumor cells based on the presence of hNQO1 activity. The overexpression of
hNQO1 in the colorectal carcinoma cell line HT-29 and the ovarian cancer cell line
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OVCAR-3 has been established.6,71 In contrast, the nonsmall cell lung carcinoma (NSCLC)
cell line H596, known to have undetectable hNQO1 activity resulting from a point mutation,
72 served as an hNQO1-negative cell line. From hNQO1-specific activity assays using
dichlorophenolindophenol (DCPIP) as an enzyme substrate,66 we validated the high activity
of hNQO1 in 24-h-old HT-29 cells (488 nmol DCPIP min−1 mg protein−1), the lower
hNQO1 activity in OVCAR-3 cells (8 nmol DCPIP min−1 mg protein−1), and undetectable
activity in H596 cells. We report here for the first time that SHIN3 cells derived from an
ovarian serous adenocarcinoma73 have overexpressed levels of hNQO1, with the activity
value (55 nmol DCPIP min−1 mg protein−1) being higher than that in OVCAR-3 cells of an
equivalent culture age (1 day). In addition, western blot analysis was used to demonstrate
hNQO1 expression in the HT-29, OVCAR-3, and SHIN3 cell lines, Figure S8. Monolayers
of all four cancer cell lines were incubated with 5 μM Q3STCy in cell culture medium for 30
min under identical conditions, followed by paraformaldehyde cell fixation. As seen in the
confocal microscopy images of Figure 5, fluorescence in the near-infrared region (660–820
nm) was found for the hNQO1-positive HT-29, OVCAR-3, and SHIN3 cell lines. These
observations indicate that the Q3STCy probe is cell membrane permeable, in agreement with
its very high log octanol-water partition coefficient of 7.9 at pH 7.4,74 and the probe is
readily activated by intracellular hNQO1. In contrast, virtually undetectable fluorescence in
this energy range was found in the hNQO1-negative H596 cell line, as expected. When cells
are exposed to the hNQO1 inhibitor dicoumarol, their subsequent incubation with the probe
leads to significantly diminished fluorescence (Figure S9), further supporting intracellular
probe activation by the upregulated hNQO1.
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So as to offer a more quantitative approach to distinguishing target cells from nontarget
(negative) cells, we calculated the target-to-background ratio (TBR), a significant index for
predicting the potency of optical imaging agents in real-time cytoreductive surgery for cell/
tissue differentiation.75 In the cases at hand, the TBR is defined as the signal from the
hNQO1-positive (HT-29, OVCAR-3, SHIN3) cells in an image compared to that from
hNQO1-negative H596 cells. TBR values reported at the 95% confidence interval are 5.4 ±
0.4 for HT-29 (53 cells)/H596 (38 cells), 3.0 ± 0.2 for OVCAR-3 (55 cells)/H596 (38 cells),
and 2.2 ± 0.2 for SHIN3 (32 cells)/H596 (32 cells). All of the TBR values are sufficiently
large to support successful use of the Q3STCy probe to identify cancerous regions during
fluorescence-guided surgery,75 as well as allow for Q3STCy probe-based assessment of
cellular hNQO1 levels in drug efficacy studies.50 Furthermore, it is important to note that the
cells were washed two times with pH 7.3 PBS prior to their being fixed and imaged; that the
TBR values remain high after this process points to significant retention of the
intracellularly produced TCy reporter from the Q3STCy probe.

Author Manuscript

To further demonstrate the difference in fluorescence signal observed in the cell images is
indeed caused by hNQO1 activity level, the fluorescence turn on of Q3STCy was evaluated
in an hNQO1 gene-transfected H596 cell line and in the wild-type, hNQO1-negative H596
cell line, Figure S10. The difference in hNQO1 activity in the wild-type versus transfected
H596 cells was proven by measuring the specific activity of hNQO1 from cellular protein
extracts using dichlorophenolindophenol (DCPIP) as an hNQO1 substrate;66 in addition, the
expression of hNQO1 in the gene-transfected H596 cell line and its absence in the wild-type,
hNQO1-negative H596 cell line were demonstrated with western blot analysis of cell
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lysates, Figure S8. From confocal microscopy images, limited fluorescence was observed in
wild-type H596 cells, while an approximately 3-fold (3.1 ± 0.3; 95% confidence interval)
larger fluorescence intensity was observed in the transfected H596 cells. These experiments
clearly show that intracellular conversion of the Q3STCy probe to the fluorescent TCy
reporter reflects differences in hNQO1 activity, thereby allowing for identification of
hNQO1-positive cells.
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Colocalization experiments were performed with Q3STCy and organelle trackers
(mitotracker green and lysotracker green DND-26) to determine the ultimate location of TCy
in HT-29 cells resulting from its hNQO1-stimulated release within the cytosol. As shown in
Figure S11, the fluorescence derived from the released TCy reporter is colocalized well with
that of the lysotracker dye. Using the coloc 2 plugin in ImageJ, the Pearson correlation
coefficient for colocalization (PCCC) was determined to be 0.77, a value indicative of
excellent TCy/lysotracker colocalization.76 In contrast, poor colocalization of TCy and
mitotracker green was evident in fluorescence images (Figure S12), and the PCCC value of
0.28 obtained upon their statistical analysis confirmed this. Importantly, TCy released in the
cytosol accumulates in the lysosomes and/or late endosomes, allowing for its enhanced
intracellular retention. We posit the high TBR values in hNQO1-positive cells result from
this reporter retention effect. Furthermore, these outcomes are significant, as certain
tricarbocyanine dyes tend to accumulate in the mitochondria, resulting in deleterious effects.
77,78 Cytotoxicity studies with HT-29 cells using 1–2 μM probe in DMSO/PBS buffer for 3h incubations indicate that cell viability (93.4 ± 2.1% and 88.1 ± 1.1%, respectively) is not
significantly impacted.
hNQO1 Activity-based Fluorescence Imaging of Multicellular Tumor Spheroids (MCTSs).
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The shortcomings associated with cell monolayers and the high cost and limited availability
of xenograft models in animals, when applied to screening assays, are major hurdles in the
successful development of drugs. This is particularly problematic for materials that target
solid tumors, as it is often the case that promising preclinical outcomes derived from cell
monolayer-based assays do not translate to the patient in the clinic.79 As a result, the use of
three-dimensional multicellular tumor spheroids (MCTSs) in drug evaluation studies is seen
as a pathway toward improved patient outcomes.29 This potential is based on the fact that
MCTSs closely resemble avascular tumors, whose interiors possess cells that are either dead
or near death (senescent) due to an acidic/hypoxic environment unlike that found for
monolayer cultures that respond well to drug candidates. The distinct behavior of promising
enzyme-activatable drugs within MCTSs is most likely the result of temporospatial enzyme
activities that are dictated by the microenvironment of the MCTSs.27 Furthermore,
laboratory-cultured MCTSs resemble multicellular aggregates isolated from ascites of
ovarian cancer patients whose disease has spread by intraperitoneal dissemination, a
progression route also common to colorectal, gastric, and pancreatic cancers.80,81 These
multicellular aggregates are ticking time bombs that upon initial attachment to the peritoneal
lining82 are too small to be readily identified by surgeons during cytoreductive surgery,75 are
isolated from the vasculature necessary for effective transmission of chemotherapeutic drugs
designed to kill them, and are suggested to be resistant to such therapeutic agents due to a
microenvironment that is mimicked by MCTSs. Thus, it is highly valuable to evaluate the
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ability of enzyme-responsive, fluorescence-based probes to be turned on inside cells of
submillimeter-sized MCTSs. Such knowledge has immediate implications for fluorescenceguided surgical approaches and longer term ramifications in studies of the spatial
dependence of upregulated target enzymes in three-dimensional cell assay applications.
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Exposure of live colorectal cancer MCTSs to Q3STCy probe leads to its rapid uptake and
subsequent hNQO1 activation to yield the TCy reporter, as noted in wide-field fluorescence
microscopy images, Figure 6. We selected MCTSs of advanced culturing age because their
microenvironment more closely reflects that of multicellular aggregates and avascular
metastases in vivo,30,83 with the 23-day-old HT-29 MCTSs used here having a ~ 100-μmthick viable cell layer at the periphery and a highly hypoxic, necrotic core. Although the
measured fluorescent signal from the TCy reporter using the Cy5 filter (λem = 662–738 nm)
is distinct from that of its precursors, the recorded response with the Cy7 filter (λem = 765–
855 nm) reflects the summed fluorescence of the Q3STCy probe and any STCy intermediate
possibly present. Prior to probe introduction, there is no significant fluorescence present in
either detection channel. However, exposure of the MCTSs to the Q3STCy probe leads to
almost immediate increases in fluorescence, as noted by both the micrographs and total
MCTS fluorescence intensity from said images. Relatively linear time-dependent fluorescent
responses are observed for both emission ranges in the entire MCTS region of interest
during the 3-h experimental period, the longest time used. We attribute the heterogeneity of
TCy reporter fluorescence (brighter near periphery) to an hNQO1 activity in the ~100-μmthick viable cell layer that is much higher than in the necrotic core of the 23-day-old
spheroids; MCTSs cultured for 15 days or less do not exhibit such a core of dead and dying
cells.84 In sum, the outcomes from the MCTS studies indicate that the activatable Q3STCy
probe quickly penetrates into the three-dimensional cancer tumor mimics and gains entry to
their component cells, where it reports on cytosolic hNQO1 activity.
Identification of Peritoneal Ovarian Cancer Micrometastases in an in Vivo Mouse Xenograft
Model.

Author Manuscript

Having demonstrated successful detection of upregulated hNQO1 activity within various
cancer cell lines cultured in two and three dimensions, we wished to explore the potential of
the Q3STCy probe for in vivo identification of tiny cancer foci in an animal model. The
ability to visualize and surgically remove <1-mm-diameter metastatic lesions that result
from intraperitoneal dissemination will have important ramifications in the treatment of
colorectal, gastric, pancreatic, and ovarian cancers. For example, it has been shown that the
median overall survival of patients is twice as great (64 months) if the surgeon is able to
remove ovarian cancer tumors less than 1 mm in dimension versus patients with residual
diseased tissue larger than 1 mm.85
Successful resection of such small cancers is predicated on their identification/detection, a
feat impeded by poor differentiation of diseased and healthy tissues during traditional white
light examination.31,75 Fluorescence-guided surgery31–33 that is based on topical application
of activatable probes holds much promise for discrimination of tissues,86–88 because such
turn-on probes outshine their always-on fluorescent counterparts as a result of increased
target-to-background signal ratio and exceedingly rapid nature of the visualization events,
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oftentimes on the time scale of minutes.75 Importantly, cell-permeable probes that are
activated by cancer-associated intracellular enzyme targets to yield cell-retained fluorescent
reporters hold the possibility of providing diseased/healthy tissue discrimination with near
cellular resolution. To date, only two intracellular enzyme-probe systems have been used to
detect human cancers in preclinical studies, namely, one based on β-galactosidase89 that is
overexpressed in ovarian cancers and another targeting hexosaminidase, which is
upregulated in colorectal cancer cells;90 both enzymes reside in the lysosomes.
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Exposure of peritoneal xenograft tumors in living mice to dilute solutions of Q3STCy probe
subsequently affords ready detection of ovarian cancer tumors as small as ~0.5 mm in
dimension, Figure 7. Although imperceptible by white light, the tiny ovarian cancer tumors
are clearly visible in spectral images of the excised mesentery that correspond to the red
fluorescent protein (RFP)-transfected SHIN3 cells and their interaction with the Q3STCy
probe. We selected the low hNQO1-expressing SHIN3 cells in the xenograft studies so as to
demonstrate the capabilities of the Q3STCy probe. Under the same imaging conditions as
xenograft animals, there were no detectable signals in control animals that did not possess
tumors (Figure 7, control). Importantly, spectral acquisition and unmixing allows for
examination of the integrity of cancer foci identification by the Q3STCy probe, which is
achieved by a side-by-side comparison of the resulting “Q3STCy image” and the “RFP
image” produced by the genetically encoded fluorescent protein in the SHIN3-DsRed
ovarian cancer cells.91 As seen in Figure 7, the fluorescence signal generated by Q3STCy
incubation in the peritoneum of mice possessing SHIN3-DsRed tumors is mostly coincident
with RFP-positive foci, thereby demonstrating the ability of the NIR probe to identify the
presence of the hNQO1-overexpressing SHIN3 cells. However, in the Q3STCy image, the
fluorescence signal is sometimes noted in areas of the small bowel adjacent to the RFPlabeled tumor nodules, suggesting possible nonspecific activation of the probe within
healthy, neighboring cells in these regions. We posit this observation is actually due to probe
activation in healthy cells having higher-than-normal hNQO1 activity that results from their
being stimulated by products released from their cancer cell neighbors. Such a scenario is
supported by reports of higher-than-normal hNQO1 expression within some healthy tissues
in immediate proximity to cancerous tissue;92 this was attributed to induced hNQO1 activity
in normal tissue cells by membrane-permeable materials released from tumor cells,93,94 with
said inducing agents potentially being the cause of increased hNQO1 activity in cancer cells
cultured at high cell density.95,96 This observation with hNQO1 may eventually lead to
limitations in the resolution of surgical resections that rely upon hNQO1-based probes,
similar to what is possible with extracellularly activated probes whose reporters may enter
cancerous and nearby healthy cells.
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It is of particular note that short exposure times and dilute concentrations of Q3STCy probe
in the peritoneum result in effective identification of peritoneally disseminated ovarian
cancer by fluorescence-activated imaging, in a spectral range that allows for deep
penetration of light into tissue. These outcomes are quite valuable, as the construction and
successful use of NIR probes and reporters for in vivo biomedical imaging applications is
exceedingly challenging. Development of enzyme-activatable, cell-penetrable NIR probes is
complicated by the multitude of structure and size limitations imposed on the probe,
oftentimes making so poor the efficiency of enzymatic activation that topical application of
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the probe is no longer feasible. As a result, the use of intravenously delivered always-on
fluorescent molecules that target cell surface uptake receptors has been extensively
investigated, but they oftentimes yield high background fluorescence signals that decrease
the TBR due to their being taken up by cancer tissue in nonspecific92 or inefficient97 ways.
Although synthetic elaboration of the structure of tissue-targeting NIR molecules can yield a
lower background signal,98 the time needed for them to reach the target site is large. Also,
due to their intravenous delivery at relatively high concentrations, they face the prospect of
regulatory agency approval, similar to that for new drug molecules.31 Furthermore,
systemically introduced reporters cannot access remote diseased tissues, such as
multicellular tumor spheroids associated with ovarian cancer metastasis and reoccurrence.80
Thus, our achievements with the Q3STCy NIR probe demonstrate the strength of locally
applied, activatable molecules for fluorescence-based identification of diseased tissues,
particularly those overexpressing reductases that are key to disease progression.
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Conclusions
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We have developed a novel NIR probe that provides high-fidelity detection and visualization
of endogenous intracellular NAD(P)H quinone reductase activity in two- and threedimensional cancer cell cultures and an in vivo preclinical model of peritoneally
disseminated ovarian cancer. hNQO1-specific reductive activation of the carefully crafted,
electron-transfer-quenched probe leads to autonomous release of its corresponding
tricarbocyanine reporter, which possesses an NIR fluorescence emission that is energetically
distinct and several orders of magnitude more intense than that of the inactive probe. The
characteristic target-to-background signal provided by the probe/reporter system allows for
facile microscopic detection and differentiation of human cancer cells possessing varied
hNQO1 activity levels, including cells experiencing different microenvironments as a result
of their location in multicellular tumor mimics. Local application of dilute solutions of the
probe in mouse xenograft models leads to identification of human ovarian cancer tumors as
small as 0.5 mm in dimension. In total, the quinone reductase-activatable probe holds much
promise in the evaluation of drug action and efficacy in clinically relevant tumor models and
preclinical animal investigations that address the specificity and sensitivity of microtumor
detection, the latter a topic of current investigation in our laboratories.
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Scheme 1. Proposed TCy Reporter Release Path and Fluorescence Turn on by Treatment of
Q33STCy with hNQO1
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Spectra of 2 μM solutions in 1% DMSO/0.1 M PBS/0.1 M KCl solution (pH = 7.4). (A)
Absorption and (B) emission spectra of TCy (red), Q3TCy (black), and iBuTCy (dashed).
Emission spectra were measured with λex = 600 nm. T =25°C.
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Figure 2.
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Time-dependent spectral changes initiated by the addition of hNQO1 (688 U mL−1) with
100 μM NADH cofactor in 0.1 M PBS/0.1 M KCl solution (pH = 7.4) containing 0.007%
BSA (U = 1 nmol of cytochrome c reduced min−1). (A) Absorption (2 μM Q3STCy) spectra
and corresponding change in absorbance maximum for the probe and reporter. (B) Emission
(4 μM Q3STCy) spectra and associated increase at the peak emission of the TCy reporter.
Color changes are demonstrated by the inset in A. Absorption spectra were measured every
1 min, and emission spectra were recorded every 4 min; λex = 605 nm, excitation slit width
= 5.0, emission slit width = 7.5. T =37°C.
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(A) Kinetic plot of hNQO1 (0.5 × 10−6 g mL−1, 250 U mL−1) with Q3STCy as a substrate in
pH 7.4, 0.1 M PBS solution containing 0.007% BSA and 100 μM NADH. Values shown are
the average of three trials with errors bars being ±1 standard deviation; line is best fit to data
(χ2 = 0.00076). (B) The fluorescence (λex = 605 nm, λem = 755 nm) from a 4 μM solution
of Q3STCy was recorded with or without the addition of 688 U mL−1 hNQO1 at the 20 min
time point. T =37 °C.
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Figure 4.

Fluorescence (λem = 755 nm, λex = 600 nm) from solutions of 4 μM Q3STCy after 20 min
of incubation at 37 °C with various reducing agents and reductase enzymes in pH 7.4, 0.1 M
PBS. Reducing agent concentrations: 1 mM for ascorbic acid (AA) and thiols, 100 μM for
NRH cofactor of NRH:quinone oxidoreductase 2 (NQO2), and 100 μM for NADH and
NADPH. The reductases were present at 688 U mL−1 for hNQO1, 617 U mL−1 for NQO2,
and 14.1 U mL−1 for cytochrome P450 reductase (CPR).
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Confocal and differential interference contrast (DIC) images of 24-h-old H596 (negative),
OVCAR-3 (positive), HT-29 (positive), and SHIN3 (positive) cells incubated with 5 μM
Q3STCy for 30 min at 37 °C. Fluorescence images were obtained using 633 nm excitation
and 660–820 nm emission. A 1.0 Airy pinhole was used. Scale bar represents 20 μm.
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Figure 6.

Representative wide-field micrographs of living HT-29 colorectal cancer multicellular tumor
spheroids (23 days old, 970 ± 24 μm diameter) in RPMI-1640 medium that were exposed to
5 μM Q3STCy at 37 °C for different times. Images were captured every 30 min using a
Leica DM6 microscope with Cy7 (λex = 672–748 nm, λem = 765–855 nm; 50 ms exposure
time) and Cy5 (λex = 590–650 nm, λem = 662–738 nm; 500 ms exposure time) filters. Note
the necrotic core (dark center) in the differential interference contrast (DIC) images. Scale
bar represents 200 μm. The control is a spheroid in medium without added probe. Reported
fluorescence values are the average of measurements from four different spheroids, with
error bars of ±1 standard deviation.
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Figure 7.

Visualization of peritoneal metastases in SHIN3 mouse model of human ovarian cancer via
fluorescence spectral imaging of mesentery at 1 h post intraperitoneal administration of
Q3STCy (300 μL of 100 μM probe in pH 7.4 PBS). Red fluorescent protein (RFP) signal
results from the RFP-transfected cells (SHIN3-DsRed). Control designates mouse having no
xenograft and treated with Q3STCy. Scale bar represents 5 mm.
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